DIABETIC RETINOPATHY MARKET ANALYSIS

Market Challenges And Opportunities

Global Diabetic Retinopathy - Market Dynamics

Increasing incidence of diabetes along with increasing cases of blindness due to diabetes are expected to drive the diabetic retinopathy market growth. According to the International Diabetic Federation report, 2017, around 425 million adults of age group 20 to 79 years are suffering from diabetes. According to the International Agency for the Prevention of Blindness, 2016, one in three people having diabetes have high chances of getting affected by diabetic retinopathy. Moreover, according to the article published in The Lancet, 2018, the annual incidence of diabetic retinopathy ranges from 2.2% to 12.7%, globally.

Moreover, several launches and approvals of new diabetic retinopathy medications are expected to boost growth of the diabetic retinopathy market over the forecast period. For instance, in May 2019, Regeneron Pharmaceutical received the U.S. Food and Drug Administration (FDA) approval for EYLEA, an aflibercept injection for diabetes retinopathy. EYLEA is the only vascular endothelial growth factor (VEGF) inhibitor approved in two dosing options for diabetes retinopathy, allowing doctors to customize treatment as per patient need.